Recruiting
Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC
NCT07447570
- Conditions
- Anti-PD-1/CTLA-4 Antibody, Carcinoma, Carcinoma, Squamous Cell, +8 more
- Locations
-
- Second Affiliated Hospital Of Zhejiang University School of Medicine Hangzhou, Zhejiang, China